VASOACTIVE INTESTINAL PEPTIDE FUSION PROTEINS FOR THE TREATMENT OF COVID-19
The present disclosure provides methods of treating inflammatory lung conditions such as COVID-19 with a fusion protein comprising a vasoactive intestinal peptide (VIP) and an elastin-like peptide.
1 . A method of treating inflammatory lung disease comprising administering a pharmaceutical composition comprising Vasoactive Intestinal Peptide (VIP) and an elastin-like peptide (ELP) to a patient in need thereof.
2 . The method of claim 1 , wherein the pharmaceutical composition comprises the polypeptide of SEQ ID NO: 3.
3 . The method of claim 1 or 2 , wherein the patient is infected by, or presumed to be infected by, a coronavirus.
4 . The method of any of claims 1 - 3 , wherein the patient is infected by, or presumed to be infected by, SARS-CoV-2, SARS, or MERS.
5 . The method of claim 4 , wherein the patient has developed COVID-19 or symptoms thereof.
6 . The method of claim 5 , wherein the patient has developed severe COVID-19 or symptoms thereof.
7 . The method of claim 5 , wherein the patient is at high risk of developing severe COVID-19 or symptoms thereof.
8 . The method of any one of claims 1 - 7 , wherein the patient presents with a comorbidity.
9 . The method of claim 8 , wherein the comorbidity increases the risk of the patient developing severe COVID-19 or symptoms thereof.
10 . The method of claim 9 , wherein the comorbidity is selected from the group consisting of: obesity, hypertension, diabetes, an autoimmune disorder (e.g. rheumatoid arthritis), heart disease, heart failure, atherosclerosis, cancer (e.g. lung cancer), a history of smoking or exposure to other lung-damaging agents), liver disease, alcoholism, other pulmonary infection, and chronic kidney disease.
11 . The method of any one of claims 1 - 9 , wherein one or more factors increasing patient risk of developing severe COVID-19 is race and/or socioeconomic status.
12 . The method of any one of claims 1 - 11 , wherein the patient presents with elevated markers of cardiac injury or dysfunction.
13 . The method of any one of claims 1 - 12 , wherein the patient presents with one or more of the following symptoms:
a) low oxygen saturation levels;
b) increased respiration rate;
c) requires oxygen therapy;
d) requires a ventilator to breathe; and
e) fever.
14 . The method of any one of claims 1 - 13 , wherein the patient is administered a low dose of the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3.
15 . The method of claim 14 , wherein the patient is administered a dose of about 10 mg of the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3.
16 . The method of claim 15 , wherein the patient is administered a low dose of the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3 for four weeks or until hospital discharge.
17 . The method of any one of claims 1 - 13 , wherein the patient is administered a moderate dose of the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3.
18 . The method of claim 17 , wherein the patient is administered a dose of about 40 mg of the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3.
19 . The method of claim 18 , wherein the patient is administered a moderate dose of the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3 for four weeks or until hospital discharge.
20 . The method of any one of claims 1 - 13 , wherein the patient is administered a high dose of the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3.
21 . The method of claim 20 , wherein the patient is administered a dose of about 100 mg of the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3.
22 . The method of claim 21 , wherein the patient is administered a high dose of the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3 for four weeks or until hospital discharge.
23 . The method of any one of claims 1 - 22 , wherein the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3 is administered subcutaneously.
24 . A method of treating a patient exhibiting one or more symptoms of SARS-CoV-2 infection, comprising administering and effective amount of a pharmaceutical composition comprising a Vasoactive Intestinal Peptide and an Elastin-like peptide (ELP).
25 . The method of claim 24 , wherein the pharmaceutical composition is administered prior to the development of Acute Respiratory Distress Syndrome (ARDS) in the patient.
26 . The method of claim 25 , wherein the pharmaceutical composition is administered when the patient is exhibiting one or more symptoms of ARDS.
27 . The method of any one of claims 24 to 26 , wherein administration of the pharmaceutical composition prevents the onset or progression of ARDS in the patient.
28 . The method of any one of claims 24 to 27 , wherein the pharmaceutical composition comprises the polypeptide of SEQ ID NO: 3.
29 . The method of any one of claims 24 - 28 , wherein the patient presents with a comorbidity.
30 . The method of claim 29 , wherein the comorbidity increases the risk of the patient developing ARDS or symptoms thereof.
31 . The method of claim 30 , wherein the comorbidity is selected from the group consisting of: obesity, hypertension, diabetes, an autoimmune disorder (e.g. rheumatoid arthritis), heart disease, heart failure, atherosclerosis, cancer (e.g. lung cancer), a history of smoking or exposure to other lung-damaging agents), liver disease, alcoholism, other pulmonary infection, and chronic kidney disease.
32 . The method of any one of claims 29 - 30 , wherein one or more factors increasing patient risk of developing ARDS is race and/or socioeconomic status.
33 . The method of any one of claims 24 to 32 , wherein the patient presents with elevated markers of cardiac injury or dysfunction.
34 . The method of any one of claims 24 - 33 , wherein the patient presents with one or more of the following symptoms:
a) low oxygen saturation levels;
b) increased respiration rate;
c) requires oxygen therapy;
d) requires a ventilator to breathe; and
e) fever.
35 . The method of any one of claims 24 - 34 , wherein the patient is administered a low dose of the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3.
36 . The method of claim 35 , wherein the patient is administered a dose of about 10 mg of the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3.
37 . The method of claim 36 , wherein the patient is administered a low dose of the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3 for four weeks or until hospital discharge.
38 . The method of any one of claims 24 - 34 , wherein the patient is administered a moderate dose of the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3.
39 . The method of claim 38 , wherein the patient is administered a dose of about 40 mg of the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3.
40 . The method of claim 39 , wherein the patient is administered a moderate dose of the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3 for four weeks or until hospital discharge.
41 . The method of any one of claims 24 - 34 , wherein the patient is administered a high dose of the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3.
42 . The method of claim 41 , wherein the patient is administered a dose of about 100 mg of the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3.
43 . The method of claim 42 , wherein the patient is administered a high dose of the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3 for four weeks or until hospital discharge.
44 . The method of any one of claims 24 - 43 , wherein the pharmaceutical composition comprising the polypeptide of SEQ ID NO: 3 is administered subcutaneously.